Tajikistan Medical Device Pharmacovigilance Obligations: Reporting Duties under Law No. 1893

1. Key takeaways

After Law No. 1893 was reissued by Law No. 2181 of May 14, 2025, Tajikistan formally wrote medical products, including medical devices, into the mandatory pharmacovigilance reporting chain. Article 20(3) lists three categories of mandatory reporting entities — manufacturers, holders of registration certificates for medicines and medical products, and medical and pharmaceutical professionals — and all of them must notify the State Supervisory Authority for Pharmaceutical Activity of adverse reactions found in products. GRZAN highlights two points. First, the object of reporting is the adverse reaction itself, and the provision sets no severity threshold. Second, the three categories of entities bear independent reporting obligations, and a report filed by one entity does not exempt any of the others. This is the ongoing compliance obligation that Chinese manufacturers most easily overlook after entering the Tajikistan market.

2. Legal basis

3. Expert insights

Insight 1: the whole of Article 20 appears in the version reissued by the 2025 Law No. 2181 and is one of the provisions most extensively changed in this revision. The title of the article was expanded from pharmacovigilance of medicines to pharmacovigilance of medicines and medical products, and all five paragraphs carry the 2025 annotation. This form shows that device vigilance is not an interpretive expansion by an administrative authority but an explicit statutory inclusion at the legislative level. When building their systems, companies no longer need to argue whether devices fall within scope.

Insight 2: Article 1(13) and Article 20(1) form a two-layer structure of standards plus system. Article 1(13) writes good pharmacovigilance practice (GVP) into the list of good pharmaceutical practice standards alongside GLP, GCP, GMP, GPP and GDP, while Article 20(1) requires the Ministry of Health to ensure the operation of the system in accordance with GVP. The legal effect is that device vigilance is upgraded from an administrative initiative to a standards-driven statutory obligation, and companies should not postpone building their systems on the ground that implementing rules have not yet been seen.

Insight 3: the obligations under Article 20(2) and Article 20(3) differ in level, and the lists of entities differ as well. Paragraph 2 is a monitoring obligation whose subjects are entities engaged in medical and pharmaceutical activity and registration certificate holders; paragraph 3 is a reporting obligation whose subjects are manufacturers, registration certificate holders, and medical and pharmaceutical professionals. The GRZAN approach is to position the registration certificate holder as a dual node for both monitoring and reporting, while establishing a parallel direct reporting channel on the manufacturer side, so that reliance on a single route does not lead to missed reports.

Insight 4: the reporting object under Article 20(3) is adverse reactions; the provision sets no severity threshold and no reporting deadline. Unlike the design adopted in some markets, where serious events must be reported within a fixed number of days, Tajikistan applies a generalized, threshold-free reporting obligation. GRZAN operates on a report-upon-detection basis; as for a specific reporting deadline, no statutory number of days has been located in Law No. 1893 or in published departmental rules, and any claim of a 72-hour reporting deadline is a practical estimate only and must not be cited as a regulatory conclusion.

Insight 5: Article 8(9) and Article 9(9) create a division of labor between rule making and supervisory enforcement. The Ministry of Health is responsible for determining vigilance procedures, while the supervisory authority receives reports and carries out pharmacological and pharmaceutical supervision. The direct impact on companies is that the receiving authority for reports is the State Supervisory Authority for Pharmaceutical Activity, not the Ministry of Health, and the choice of channel must not be confused.

Insight 6: the vigilance obligation is directly linked to Article 21(1)(5). That withdrawal ground provides that where the registration certificate holder and the manufacturer fail to fulfill the obligation to monitor adverse reactions, as well as the obligations to monitor safety, quality and effectiveness, this constitutes a statutory ground for withdrawal from circulation. This means that the consequence of a failed vigilance system is not limited to liability pursuit; it also directly triggers market withdrawal.

4. Practical recommendations

1. Rebuild the vigilance system to the GVP standard of Article 20(1) and bring devices into its coverage. Under Article 1(13) and Article 20(1), the existing medicine vigilance system must be extended to medical products, covering four links: collection, assessment, reporting and implementation of measures for adverse reactions.
2. Position the registration certificate holder as the primary node for monitoring and reporting. Under Article 20(2) and (3), define in the entity structure that the holder bears the dual duties of monitoring and reporting, while the manufacturer maintains a parallel direct reporting channel.
3. Collect adverse reaction information on a threshold-free basis. Under Article 20(3), the scope of collection is not limited to serious cases; establish feedback mechanisms with local distributors and clinical institutions to ensure that information from the side of medical and pharmaceutical professionals is reachable.
4. Lock the receiving authority for reports as the State Supervisory Authority for Pharmaceutical Activity. Under Article 9(9), establish a standing communication channel with that authority and retain proof of each submission.
5. Manage vigilance failure as a linked market withdrawal risk. Under Article 21(1)(5), list failure to fulfill the adverse reaction monitoring obligation as a top-level risk item in the internal risk register.

5. Verification checklist

• □ Confirmed that all five paragraphs of Article 20 appear in the version reissued by Law No. 2181 of May 14, 2025
• □ Confirmed that Article 1(13) includes good pharmacovigilance practice (GVP) in the list of good pharmaceutical practice standards
• □ Confirmed that the three categories of mandatory reporting entities under Article 20(3) are manufacturers, registration certificate holders and medical and pharmaceutical professionals
• □ Confirmed that the reporting object under Article 20(3) is adverse reactions and that no severity threshold is set
• □ Confirmed that the current law sets no specific reporting deadline (claims such as a 72-hour deadline have not been adopted)
• □ Established a reporting process with the registration certificate holder as the primary node and the manufacturer as a parallel channel
• □ Confirmed that the receiving authority for reports is the State Supervisory Authority for Pharmaceutical Activity (Article 9(9))
• □ Included the withdrawal risk of Article 21(1)(5) in the contingency plan for vigilance system failure

Regulatory information verified as of October 29, 2026.

In the Central Asia market, the core capabilities of GRZAN concentrate on three points. First, distinguishing the different legal positions of individual markets within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states, where a national pathway and a Union pathway both exist; Uzbekistan is an observer state with only a national pathway; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services, which may act as the statutory representative of manufacturers in these countries and assume registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com